Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13

Abstract

Multiple myeloma (MM) is a hematologic cancer arising from plasma cells. Mesenchymal stem cells (MSCs) are a heterogeneous cell population in the bone marrow microenvironment. In this study, we evaluated the regulatory effects of MSCs on the invasion and drug resistance of MM cells U266 and LP-1. Bone marrow samples from MM patients and normal subjects were collected. MSCs were extracted from bone marrow and cultured, and their phenotypes were identified by flow cytometry. The level of CXCL13 in the supernatant of cultured MSCs was detected by ELISA. The protein expression of CXCR5 (a specific receptor of CXCL13) in U266 and LP-1 cells was detected by Western blot. The effects of MSCs on the invasion of U266 and LP-1 cells and the resistance to bortezomib were assessed by Transwell and CCK-8 assay, respectively. The mRNA and protein expressions of BTK, NF-κB, BCL-2, and MDR-1 were detected by RT-PCR and Western blot, respectively. CXCL13 was secreted by MSCs in the bone marrow microenvironment, and the level in MSCs from MM patients was significantly higher than that of healthy subjects. CXCR5 was expressed in both U266 and LP-1 cells. The resistance of MM cells to bortezomib was enhanced by MSCs through CXCL13 secretion. The invasion and proliferation of U266 and LP-1 cells were promoted, and the mRNA and protein expressions of BTK, NF-κB, BCL-2, and MDR-1 were upregulated by MSCs. The basic biological functions of MM cells U266 and LP-1 were affected by MSCs via the CXCL13-mediated signaling pathway. This study provides valuable experimental evidence for clinical MM therapy.

Analysis of Circular RNA-Related Competing Endogenous RNA Identifies the Immune-Related Risk Signature for Colorectal Cancer

“…Studies have shown that inhibition of NF-κBc-Rel attenuates regulatory T cell-mediated immunosuppression and enhances the therapeutic efficacy of anti-PD-1 (Grinberg-Bleyer et al, 2017). Of the seven immune-related genes, three genes are associated with NF-κB activity (Deng et al, 2000;Kermarrec et al, 2019;Zhang et al, 2019). Therefore, it is further shown that the signature was associated with the response to immunotherapy.…”

Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance

“…Similarly, in chronic lymphoid leukemia (CLL), forodesine-induced CLL cell apoptosis was antagonized by MSCs, which inhibited forodesine-induced RNA and protein synthesis activity and increased the expression of the antiapoptotic protein Mcl-1 at both the transcript and protein levels [ 88 ]. Moreover, in multiple myeloma (MM), it was found that MSCs enhanced MM cell resistance to bortezomib through CXCL13 production [ 89 ]. In solid tumors, MSCs have also been shown to promote resistance to therapeutic therapy.…”

Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma

“…C‐C chemokine receptor type 2, which is activated by several chemokines, including MCP‐2, is known to polarize macrophages toward the M2‐like phenotype associated with drug resistance in MM 39 . It has been reported that resistance of MM cell lines to bortezomib was enhanced by mesenchymal stem cells through CXCL13 (BCA‐1) secretion 40 …”

“…39 It has been reported that resistance of MM cell lines to bortezomib was enhanced by mesenchymal stem cells through CXCL13 (BCA-1) secretion. 40 Serious toxicity can preclude optimum treatment and indirectly adversely impact on outcome. Our preliminary results indicate the potential to predict neurotoxicity using MIP-1α levels and thus stop treatment before potentially irreversible neurological damage.…”